scholarly journals Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib

2009 ◽  
pp. 83 ◽  
Author(s):  
Charles Chuah
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Targeted Treatment ◽  
Imatinib Resistant

scholarly journals MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

2009 ◽  
Vol 8 (1) ◽  
pp. 69 ◽  
Author(s):  
Edurne San José-Enériz ◽  
José Román-Gómez ◽  
Antonio Jiménez-Velasco ◽  
Leire Garate ◽  
Vanesa Martin ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Expression Profiling ◽  
Myeloid Leukemia ◽  
Microrna Expression ◽  
Imatinib Resistant ◽  
Clinically Significant

scholarly journals Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells

Oncotarget ◽  
2011 ◽  
Vol 2 (11) ◽  
pp. 874-885 ◽  
Author(s):  
Maeva Dufies ◽  
Arnaud Jacquel ◽  
Nathalie Belhacene ◽  
Guillaume Robert ◽  
Thomas Cluzeau ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Leukemia Cells ◽  
Imatinib Resistant ◽  
And Function

HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia

2014 ◽  
Vol 348 (1-2) ◽  
pp. 50-60 ◽  
Author(s):  
Sun-Mi Yun ◽  
Kyung Hee Jung ◽  
Soo Jung Kim ◽  
Zhenghuan Fang ◽  
Mi Kwon Son ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Imatinib Resistant ◽  
T315i Mutation

scholarly journals Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia

2017 ◽  
Vol 11 (2) ◽  
pp. 344-347 ◽  
Author(s):  
Vihang Patel ◽  
Anil Pattisapu ◽  
Karim Attia ◽  
John Weiss
Keyword(s):  
Acute Pancreatitis ◽  
Adverse Event ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Elderly Woman ◽  
Kinase Inhibitor ◽  
Therapeutic Class ◽  
Imatinib Resistant ◽  
Life Threatening ◽  
Novel Drug

Nilotinib, a second-generation tyrosine kinase inhibitor, is used for treatment of chronic myeloid leukemia (CML); it has been widely used especially for imatinib-resistant CML. Despite being a novel drug in this therapeutic class, it has the potential to be harmful. We present the case of an elderly woman who developed life-threatening acute pancreatitis as an adverse event after having started the drug. There is only one reported case in the literature of nilotinib-induced acute pancreatitis. The purpose of this case report is to educate physicians who prescribe this medication to be aware of potential life-threatening adverse events. As more and more therapies are available, physicians should be aware of potential effects of cancer treatment that could be life-threatening to patients.

scholarly journals PB1920 BCR-ABL GENE ABL KINASE DOMAIN MUTATIONS IN IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS FROM AZERBAIJAN

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 873-874
Author(s):  
C. Asadov ◽  
A. Hasanova ◽  
A. Shirinova ◽  
N. Karimova ◽  
Z. Alimirzoeva
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Domain ◽  
Abl Kinase ◽  
Imatinib Resistant ◽  
Kinase Domain Mutations

scholarly journals Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

2011 ◽  
Vol 14 (8) ◽  
pp. 1057-1067 ◽  
Author(s):  
Martin Hoyle ◽  
Gabriel Rogers ◽  
Tiffany Moxham ◽  
Zulian Liu ◽  
Ken Stein
Keyword(s):  
Cost Effectiveness ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Imatinib Resistant

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia

2016 ◽  
Vol 383 (2) ◽  
pp. 220-229 ◽  
Author(s):  
Pranav Gupta ◽  
Rishil J. Kathawala ◽  
Liuya Wei ◽  
Fang Wang ◽  
XiaoKun Wang ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Imatinib Resistant ◽  
T315i Mutation
Sign in / Sign up

Export Citation Format

Share Document